Discontinued — last reported Q4 '18
An increase typically reflects new capital investment or acquisition of rights, while a steady decrease indicates the systematic amortization of the asset's value over its remaining patent life.
This metric represents the carrying value of identifiable intangible assets specifically associated with the Adempas pro...
Comparable to capitalized product rights or acquired intangible assets reported by other pharmaceutical companies for specific drug franchises.
mrk_segment_adempas_intangible_assets_net_excluding_goodwill